Exploiting a low tax system: non-tax-induced cigarette price increases in Taiwan 2011-2016.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
12 2019
Historique:
received: 21 12 2018
revised: 11 04 2019
accepted: 26 04 2019
pubmed: 6 6 2019
medline: 26 6 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

This study aims to analyse the non-tax-induced price increasing strategies adopted by tobacco industry in Taiwan, a high-income country with comprehensive tobacco control policies but low tobacco taxes and a declining cigarette market. Using governmental tax, price and inflation data, we analysed cigarette sales volume, affordability, affordability elasticity of demand, market share, pricing and net revenue of the top five tobacco companies in Taiwan from 2011 to 2016 when no tax increases occurred. Total revenue after tax grew significantly for all the major transnational tobacco companies between 2011 and 2016 at the expense of the state-owned Taiwan Tobacco and Liquor Corporation. In terms of market share, Japan Tobacco (JT) was the leading company, despite experiencing a small decline, while British American Tobacco and Imperial Brands remained stable, and Philip Morris International increased from 4.7% to 7.0%. JT adopted the most effective pricing strategy by increasing the real price of its two most popular brands (Mevius and Mi-Ne) and, at the same time, doubling the sales of its cheaper and less popular brand Winston by leaving its nominal retail price unaltered. Low and unchanged tobacco taxes enable tobacco companies to use aggressive pricing and segmentation strategies to increase the real price of cigarettes without making them less affordable while simultaneously maintaining customers' loyalty. It is crucial to continue monitoring the industry's pricing strategies and to regularly increase taxes to promote public health and to prevent tobacco industry from profiting at the expense of government revenues.

Identifiants

pubmed: 31164488
pii: tobaccocontrol-2018-054908
doi: 10.1136/tobaccocontrol-2018-054908
pmc: PMC6996108
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e126-e132

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Tob Control. 2012 Mar;21(2):172-80
pubmed: 22345242
Tob Control. 2013 May;22(e1):e21-4
pubmed: 22628168
Tob Control. 2018 Sep;27(5):483
pubmed: 30127059
Tob Control. 2019 May;28(Suppl 1):s9-s19
pubmed: 30037805
Tob Control. 2017 Oct 9;:
pubmed: 28993519
Tob Control. 2010 Oct;19(5):423-30
pubmed: 20876078
Public Health. 2010 Aug;124(8):429-36
pubmed: 20655077
Asia Pac J Public Health. 2018 May;30(4):328-331
pubmed: 29719972
Tob Control. 2014 Jan;23(1):45-50
pubmed: 23322310
Tob Control. 2010 Feb;19(1):44-9
pubmed: 19965797
Tob Control. 2011 May;20(3):235-8
pubmed: 21115556
Tob Control. 2004 Dec;13(4):339-46
pubmed: 15564616
Am J Public Health. 2015 Mar;105(3):e5-8
pubmed: 25602874
BMJ. 2003 Jul 19;327(7407):154-7
pubmed: 12869461
Lancet. 2015 Mar 14;385(9972):1029-43
pubmed: 25784350
Tob Control. 2020 Jan;29(1):36-42
pubmed: 30397030
Health Policy Plan. 2011 May;26(3):266-73
pubmed: 20807857
Tob Control. 2014 Nov;23(e2):e89-97
pubmed: 24046211
Prev Med. 2017 Dec;105S:S19-S22
pubmed: 28625418
PLoS One. 2018 Dec 5;13(12):e0200665
pubmed: 30517093
Addiction. 2013 Jul;108(7):1317-26
pubmed: 23445255
Tob Control. 2014 Mar;23 Suppl 1:i48-53
pubmed: 24092600
Addiction. 2014 Jan;109(1):140-6
pubmed: 24033589
Tob Control. 1999 Summer;8(2):196-201
pubmed: 10478406
Tob Control. 2016 Jul;25(4):458-63
pubmed: 26138823

Auteurs

Wayne Gao (W)

Master's Program in Global Health and Development, Taipei Medical University, Taipei, Taiwan waynegao@tmu.edu.tw.

Mattia Sanna (M)

Master's Program in Global Health and Development, Taipei Medical University, Taipei, Taiwan.

J Robert Branston (JR)

School of Management, University of Bath, Bath, UK.

Hung-Yi Chiou (HY)

School of Public Health, Taipei Medical University, Taipei, Taiwan.

Yi-Hua Chen (YH)

School of Public Health, Taipei Medical University, Taipei, Taiwan.

Allison Wu (A)

Master's Program in Global Health and Development, Taipei Medical University, Taipei, Taiwan.

Chi Pang Wen (CP)

Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan.
China Medical University Hospital, Taichung, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH